These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. General practitioners and postmarketing surveillance. Drug Ther Bull; 1984 Oct; 22(21):83-4. PubMed ID: 6499666 [No Abstract] [Full Text] [Related]
4. [The need for 'postmarketing surveillance']. Stricker BH; in 't Veld BA; Feenstra J Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624 [TBL] [Abstract][Full Text] [Related]
5. [Drug surveillance: the concept, the need and methods]. Moreno González A An R Acad Nac Med (Madr); 1992; 109(1):197-218; discussion 218-20. PubMed ID: 1463138 [No Abstract] [Full Text] [Related]
6. The quantification of drug risks in practice. Lee D; Bergman U WHO Reg Publ Eur Ser; 1993; 45():79-95. PubMed ID: 8442852 [No Abstract] [Full Text] [Related]
7. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. Kessler DA JAMA; 1993 Jun; 269(21):2765-8. PubMed ID: 8492403 [No Abstract] [Full Text] [Related]
8. [The Medical Products Agency is responsible for the control of medical technological products: we need more active medical professionals reporting shortages]. Philipson L Lakartidningen; 2008 Mar 5-11; 105(10):746-7. PubMed ID: 18422241 [No Abstract] [Full Text] [Related]
9. The surgeon and medical devices: adverse incident reporting and off-label use. Lennard N; Coutinho M; Campbell B Ann R Coll Surg Engl; 2013 Jul; 95(5):309-10. PubMed ID: 23838490 [No Abstract] [Full Text] [Related]
10. Record linkage for postmarketing surveillance. Faich GA Clin Pharmacol Ther; 1989 Oct; 46(4):479-80. PubMed ID: 2791451 [No Abstract] [Full Text] [Related]
11. Drug safety--the role of doctors, pharmaceutical companies and the medical press. Goldberg A Br J Clin Pract; 1985 Jan; 39(1):5-6. PubMed ID: 3986100 [No Abstract] [Full Text] [Related]
12. The role of automated record linkage in the postmarketing surveillance of drug safety: a critique. Shapiro S Clin Pharmacol Ther; 1989 Oct; 46(4):371-86. PubMed ID: 2535647 [No Abstract] [Full Text] [Related]
13. Risk Evaluation and Mitigation Strategy (REMS): FDA Perspective on What Physicians Need to Know. Slatko GH Am Fam Physician; 2015 Nov; 92(9):771-2. PubMed ID: 26554468 [No Abstract] [Full Text] [Related]
14. Why should doctors get involved in medical administration? Roberts P CMAJ; 1987 Oct; 137(8):754. PubMed ID: 3651948 [No Abstract] [Full Text] [Related]
15. The role of record linkage in post-marketing drug surveillance. Crombie IK Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):77S-82S. PubMed ID: 3567036 [No Abstract] [Full Text] [Related]
16. Adverse drug event reporting. Improving the low US reporting rates. Edlavitch SA Arch Intern Med; 1988 Jul; 148(7):1499-503. PubMed ID: 3382293 [No Abstract] [Full Text] [Related]
17. Uninformed criticism of automated record linkage. Vick H; Walker AM Clin Pharmacol Ther; 1989 Oct; 46(4):478-9. PubMed ID: 2791450 [No Abstract] [Full Text] [Related]
18. The Danish strong analgesic surveillance system. Sørensen HT; Nielsen GL; Sabroe S; Hamburger H Dan Med Bull; 1997 Nov; 44(5):539-41. PubMed ID: 9408739 [TBL] [Abstract][Full Text] [Related]
19. Automated record linkage: a response to the commentary and letters to the editor. Shapiro S Clin Pharmacol Ther; 1989 Oct; 46(4):395-8. PubMed ID: 2791442 [No Abstract] [Full Text] [Related]